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Abstract
Purpose To assess the diagnostic performance of PET/MR in
patients with non-small-cell lung cancer.
Methods Fifty consecutive consenting patients who
underwent routine 18F-FDG PET/CT for potentially radically
treatable lung cancer following a staging CT scan were re-
cruited for PET/MR imaging on the same day. Two experi-
enced readers, unaware of the results with the other modali-
ties, interpreted the PET/MR images independently. Discor-
dances were resolved in consensus. PET/MR TNM staging
was compared to surgical staging from thoracotomy as the
reference standard in 33 patients. In the remaining 17 nonsur-
gical patients, TNM was determined based on histology from
biopsy, imaging results (CT and PET/CT) and follow-up.
ROC curve analysis was used to assess accuracy, sensitivity
and specificity of the PET/MR in assessing the surgical re-
sectability of primary tumour. The kappa statistic was used to
assess interobserver agreement in the PET/MRTNM staging.
Two different readers, without knowledge of the PET/MR
findings, subsequently separately reviewed the PET/CT im-
ages for TNM staging. The generalized kappa statistic was
used to determine intermodality agreement between PET/CT
and PET/MR for TNM staging.
Results ROC curve analysis showed that PET/MR had a
specificity of 92.3 % and a sensitivity of 97.3 % in the
determination of resectability with an AUC of 0.95. Interob-
server agreement in PET/MR reading ranged from substantial
to perfect between the two readers (Cohen’s kappa 0.646 – 1)
for T stage, N stage and M stage. Intermodality agreement
between PET/CT and PET/MR ranged from substantial to
almost perfect for T stage, N stage and M stage (Cohen’s
kappa 0.627 – 0.823).
Conclusion In lung cancer patients PET/MR appears to be a
robust technique for preoperative staging.
Keywords Non-small-cell lung cancer . Lung cancer . PET/
MR . TNM staging
Introduction
Non-small-cell lung cancer (NSCLC) accounts for 75 – 80 %
of all lung cancers and is currently the leading cause of
tumour-related deaths [1]. Accurate staging is critical in de-
termining management. Surgical resection is the therapeutic
standard in fit patients with stage I–IIIa disease, but unfortu-
nately the majority of patients have advanced disease at pre-
sentation [2, 3]. Imaging plays a central role in establishing an
accurate preoperative stage and directing further confirmatory
tests. Thoracic contrast-enhanced (CE) CTand 18F-FDG PET/
CT are performed to assess, respectively, morphology and
metabolic TNM stage [4, 5]. CE CT has been widely used
for the preoperative evaluation of tumour size and local extent,
but is limited in differentiating malignant from reactive
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lymphadenopathy and in detecting distant metastatic disease
[6]. FDG PET/CT has been reported to increase diagnostic
accuracy in the differentiation of benign and malignant pri-
mary cancers and to improve identification of nodal disease
and metastasis [7, 8].
MRI has been investigated as an emerging technique for
whole-body cancer staging, providing high soft tissue contrast
and potential for multiparametric tissue characterization
through diffusion and dynamic CE sequences [9–11]. Previ-
ous studies assessed the feasibility of a whole-body MR
protocol for lung cancer staging and demonstrated accuracy
similar to that of PET/CT for NSCLC staging with better
sensitivity than PET/CT for metastatic disease [12]. Com-
bined PET/MR is a new technique that has shown similar
performance to PET/CT in several, but generally small, retro-
spective studies [13, 16]. The potential advantages of the
technique include multiparametric metabolic, functional and
morphological information provided by combining radioac-
tive tracers with different MR sequences. Furthermore, the
lack of radiation using MRI is a major advantage over CT,
particularly when repeat studies are used in patient
management.
In this prospective study we compared the performance of
PET/MR with conventional lung cancer staging in patients
with potentially resectable disease.
Materials and methods
Patients
Our institutional ethics review board approved this prospec-
tive study, and informed consent was obtained from all
patients.
From May 2012 to August 2013, 50 consecutive patients
(28 men and 22 women; mean age 58 years, range 42 – 79
years) who underwent routine 18F-FDG PET/CT for poten-
tially radically treatable lung cancer following a staging CT
scan were recruited for PET/MR imaging on the same day.
The patients were referred for PET scanning for enlarged
nodes (25 patients), to help biopsy planning (8 patients), and
for suspected M1a or M1b lesions (17 patients). The interval
between CE CT and PET/CT was less than 14 days.
The PET/CT scan was performed in fasted patients using a
Discovery STe 16-slice PETCT scanner (GE Healthcare,
Milwaukee, WI) 60 min after intravenous injection of
5.5 MBq/kg of 18F-FDG. CT was performed according to a
standard protocol with the following parameters: 140 keV,
30 – 170 mAs, pitch 1.75, and section thickness 3.75 mm
(to match the PET section thickness). The mean (±standard
deviation) PET/CT scan duration was 33±4 min. The mean
effective radiation dose from the PET/CT scan was 17.2±
2.7 mSv (9.2±2.3 mSv from the PET scan).
Patients were transferred immediately to the PET/MR scan-
ner (3 T Biograph mMR; Siemens, Erlangen, Germany)
where a simultaneous PETandMR acquisition was performed
approximately 20 min (15 – 35 min) after the PET/CT exam-
ination with 5 min per bed position). Four tissue class (soft
tissue, fat, lung, air) attenuation correction maps were calcu-
lated from two-point Dixon sequences. The MR protocol for
each patient included axial T2-weighted HASTE, axial diffu-
sion (DWI) and axial T1-weighted 3-D interpolated breath-
hold examination (VIBE) with fat suppression after contrast
enhancement of the thorax and abdomen by administration of
0.2 ml/kg Gd.
Reference standard
The reference standard was histology from thoracotomy in
patients considered operable. Patients considered inoperable
were staged using results from imaging, bronchoscopy, nodal
assessment or follow up. Patients had standard care follow-up
which included CE CT+PET/CT or MR when required. A
flowchart of the reference standard TNM staging is shown in
Fig. 1.
When preoperative CT and FDG PET/CT depicted en-
larged or suspicious nodes, endobronchial ultrasonography
(EBUS), mediastinoscopy or ultrasound-guided aspiration
was performed. Patients with stage I, II or IIIA NSCLC were
considered operable. Of the 50 patients, 33 were surgically
treated, 14 underwent chemotherapy and 3 underwent radio-
therapy. None underwent radical radiotherapy.
Tumour histology was consistent with large-cell carcinoma
in 9 patients (18 %), adenocarcinoma in 28 patients (56 %)
and squamous cell carcinoma in the remaining 13 patients
(26 %). Histology was obtained preoperatively in 43 patients
from percutaneous needle aspiration biopsy (14 patients),
EBUS (18 patients), bronchoscopy (8 patients), pleural effu-
sion (1 patient), lymph node mediastinoscopy (1 patient), and
supraclavicular lymph node ultrasound-guided aspiration
(1 patient). Seven patients with highly suspicious small
lesions that were classified as stage I by the reference standard
underwent surgery prior to preoperative histological
Fig. 1 Flowchart showing how TNM stage was determined. EBUS
endobronchial ultrasound, Ultrasound biopsy of supraclavicular nodes,
VATS video-assisted thoracoscopic surgery
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assessment. Surgical pathological T stage was available in 33
patients, from thoracotomy (lobectomy in 25 patients,
bilobectomy in 4, and results in 1) in 30 patients and from
video-assisted thoracoscopic surgery resection in 3 patients.
In 17 inoperable patients (14 with stage IV disease and 3
inoperable for medical reasons) T stages were determined in
consensus using imaging, bronchoscopy or follow-up results.
N stages were determined preoperatively with EBUS in 21
patients, lymph node mediastinoscopy in 3 patients, and
supraclavicular lymph node aspiration in 2 patients. In the
33 patients who underwent thoracotomy, nodal dissection was
performed. In the remaining patients, nodes were assessed by
imaging and follow-up. Metastatic lesions were confirmed on
pathological examination in four patients. Six patients had
metastatic lesions confirmed on specific organ-dedicated or
follow-up imaging studies.
Image analysis
PET/MR data were anonymized and sen t to a
workstation(OsiriX, http://www.osirix-viewer.com/) for
evaluation. Images were interpreted by a chest radiologist
with nuclear medicine training (F.F, 10 years) and by a
radiologist with dedicated skills in MRI and also with
experience in interpreting nuclear medicine studies (S.P, 10
years). Images were interpreted first separately and then
discordant findings were resolved by consensus. Readers
were unaware of the clinical and pathological results and
imaging findings of the other modalities. PET/MR image
quality was scored subjectively on a scale of 1 to 3 (1 unac-
ceptable, 2 good, 3 excellent).
Lung cancer staging was performed following the TNM
classification (7th edition). Readers were free to evaluate
either MR images alone or fused PET/MR images in a real
time approach. Each reader recorded:
1. T stage, lesion dimension and nodal status.
2. A confidence score for each site of nodal and distant
disease (1, 2 disease unlikely, 3 possible disease, 4 prob-
able disease, 5 likely disease, and 6 definite disease).
Lymph node stations were allocated to 22 groups accord-
ing to lymph node map definitions for lung cancer staging
recommended by the International Association for the
Study of Lung Cancer.
3. Distant metastases, divided into 28 sites, recording the
category (M1a or M1b) and the anatomical location.
PET/CT images were separately reviewed for TNM
staging without knowledge of the PET/MRI findings by
two different readers (L.M., R.Z.), each with more then
5 years experience in PET.
Statistical analysis
PET/MR imaging findings were recorded in an electronic
database (Microsoft Excel 2008 for Macintosh; Microsoft,
Redmond, WA) and statistical analysis was performed
using dedicated software (SPSS 13.0 for Macintosh;
SPSS, Chicago, IL).
ROC curve analysis was performed to assess the accuracy,
sensitivity and specificity of PET/MR in assessing TNM
stage. For statistical analysis when dichotomization of data
was required, we considered 1 – 3 as negative for the presence
of disease and 4 – 6 as indicative of the presence of disease. A
p value <0.05 was considered statistically significant.
The generalized kappa statistic (κ) was used to determine
PET/MR interobserver agreement and intermodality agree-
ment (PET/CT vs. PET/MR) for TNM staging considering:
κ <0.2 as slight agreement, κ 0.21 – 0.40 as fair agree-
ment, κ 0.41 – 0.60 as moderate agreement, κ 0.61 – 0.80
as substantial agreement, and κ 0.81 – 1.00 as almost
perfect agreement [17].
Results
PET/MR examinations yielded diagnostic image quality from
good to excellent in all patients (Fig. 2). The mean PET/MR
scan time (including room time) was 38±9 min.
Fig. 2 Axial PET/MR image (a)
PET/CT image (b) and CE CT
image (c) in a 63-year-old
woman. A small nodule shows
FDG uptake on both the PET/MR
and PET/CT images
Table 1 Staging
according to the refer-




I 17/50 (34) 14/50 (28)
II 12/50 (24) 17/50 (34)
IIIa 8/50 (16) 6/50 (12)
IIIb-IV 13/50 (26) 13/50 (26)
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According to the reference standard, 17 of the 50 patients
(34 %) were classified as stage I, 12 (24 %) were classified as
stage II, 8 (16 %) were classified as stage IIIA and 13 (26 %)
were classified as stage IIIb and IV (Table 1).Agreement in T,
N and M staging between reader 1 and reader 2 was substan-
tial to excellent (Table 2). The staging results showed a high
concordance between PET/MR and the reference in most
patients. The details of the staging assessments are shown in
Tables 3, 4 and 5.
The T stage of primary tumours was correctly assessed in
37 patients (74 %). Of the remaining 13 patients (26 %), 4
(8 %) were over-staged and 9 (18 %) were under-staged. A
total of 1,100 nodal groups were evaluated on PET/MR. Of
these nodes, 51 (0.05 %) were classified as malignant, and 63
nodes (0.06 %) were classified as malignant according to the
reference standard. Metastatic lesions were confirmed in 18
organs in ten patients (ten bone, three liver, one kidney, three
adrenal, one soft tissue). A complete agreement in all findings
(T, N and M) with identical nodal and metastasis locations
between PET/MR and the reference standard was achieved in
26 patients. Differences in T, N and M staging, but with
resectability agreement, were found in 22 patients. Differ-
ences in T, N and M staging affecting resectability were found
in two patients. In one patient a moderately FDG-avid
supraclavicular lymph node was visible on PET/MR images
(Fig. 3). No nodal metastases were found in this patient on
histological examination. One patient (Fig. 4) presented with a
paravertebral lesion, which was considered resectable on PET/
MR. In this patient, surgical examination revealed infiltration
of the vertebral body.
Overall the ROC curve analysis (Fig. 5) showed that PET/
MR had a specificity of 92.3 % and a sensitivity of 97.3 % in
the determination of resectability with an AUC of
0.95.Intermodality agreement was from substantial to almost
perfect for T stage, N stage and M stage (κ 0.627 – 0.823).
None of the discrepancies affected clinical management
(Fig. 6). PET/MR revealed five suspicious (>5 mm) FDG-
avid nodules of the 13 identified on PET/CT. One small
minimally avid subsolid lesion not identified on PET/MR
was detected on PET/CT and was considered as disease.
PET/MR revealed liver metastasis in four patients, that was
identified on PET/CT in three. PET/MR detected two non-
avid bone lesions that were not seen on PET/CT.
Discussion
CT and PET are essential imaging techniques for clinical
staging before treatment although with the disadvantage of
exposure to ionizing radiation. Therefore two separate scans
are often performed at different times, potentially resulting in
delays in patient evaluation and staging by the local multidis-
ciplinary team. The feasibility of PET/MR as an alternative to
PET/CT has recently been demonstrated in a range of dis-
eases, although in limited or heterogeneous cohorts [13–16].
In a comparative evaluation of PET/MR alone versus PET/CT
alone in a selected cohort of oncology patients with different
cancers, Catalano et al. [18] found that the performance of
PET/MR alone more often resulted in a change in clinical
management. These authors also acknowledged that in select-
ed anatomical regions, such as the pelvis or head and neck
region, the intrinsic contrast resolution of MR allows better
delineation of tissue anatomy, including margins, local infil-
tration, and the relationship of tumours to adjacent structures,
than is possible with CT.
PET/MR was recently compared with PET/CT for lung
cancer staging in a small pilot study [19]. The new modality
Table 3 T staging
according to the refer-
ence and PET/MR
PET/MR Reference
T1 T2 T3 T4
T1 12 0 2 1
T2 1 11 2 4
T3 0 2 9 0
T4 0 1 0 5
Table 4 N staging
according to the refer-
ence and PET/MR
PET/MR Reference
N0 N1 N2 N3
N0 23 4 1 0
N1 4 3 1 0
N2 1 0 6 0
N3 0 2 0 5
Table 5 M staging




M0 40 1 1
M1a 0 1 1
M1b 0 0 6
Table 2 Agreement in T, N andM staging between reader 1 and reader 2
(Cohen's κ)
Cohen’s κ Standard deviation p value
T 0.753 0.069 0.000
N 0.646 0.089 0.000
M 1.000 0.000 0.000
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was shown to be a potential alternative to PET/CT, with
adequate diagnostic image quality. While modality-specific
differences were not described, a reference standard was lack-
ing, as this was a feasibility report. Heuch et al. have recently
compared a dedicated pulmonary PET/MR protocol and 18F-
FDG PET/CT in a cohort of 22 patients who received surgery
[20]. The authors found that the two modalities had the same
accuracy (100 %) in T and N staging compared with
histopathology.
In our study we used a combination of surgical information
and an enhanced reference standard derived fromCT, PET/CT
and histopathology to assess the performance of PET/MR in
the evaluation of lung cancer resectability. Our results dem-
onstrate a high accuracy of PET/MR with high specificity and
sensitivity for this purpose. We found differences between
PET/MR and the reference standard. However, clinical man-
agement would have been altered in only two patients. In one,
disease was considered unresectable owing to suspected N3
disease on PET/MR, whereas the reference standard indicated
resectability. In this patient PET/CTwas normal. We postulat-
ed that an increased FDG uptake might have occurred in
benign lymph node with chronic inflammation as reported
previously [20]. In the second patient, with a lesion adjacent
to the vertebral body, PET/MR images suggest a preserved fat
plane, while the disease was unresectable at the time of
surgery.
Comparing PET/MR with the reference standard for T
staging, we found that the technique slightly overestimated
T1 and T2 stages but appeared to underestimate higher stages,
i.e. T3 and T4. Our findings are somewhat different from the
experience of Yi et al. [12] who reported high diagnostic
accuracy of a dedicated whole-body MR protocol for lung
cancer staging. However, we decided to use a nondedicated
lung protocol (with a shorter acquisition time) and this may
have impaired spatial resolution, with a particular impact on
delineation of the relationship between tumour and adjacent
structures. We found good agreement between PET/MR and
the reference standard in N staging with few discrepancies,
only one of which was considered to have affected resectabil-
ity where PET/MR was read as N3 but the node was not
malignant on histology. Previous investigators have reported
an overestimation of FDG uptake when using PET/MR. Al-
Nabhani et al. [14] reported that the performance of PET/MR
after PET/CT resulted in delayed tracer accumulation with
increasing lesion to background uptake within the lesion,
and suggested that this may alter reader perception in
assessing nodal disease.
PET/CT has been shown to be associated with a false-
positive rate of up to 40 % making histological confirmation
of any FDG-avid deposit very important [21]. In our study six
patients were understaged by PET/MR. They showed no
uptake and were positive on histological examination. In this
regard, since PET/MR is a new modality, its interpretation is
not as straightforward as for CT or PET/CT and requires a
combination of anatomical, metabolic and functional informa-
tion. In comparison with PET/CT, the MR component might
provide better anatomical localization owing to higher resolu-
tion with better contrast on T1-weighted imaging, T2 HASTE
and DWI/ADC images.
With respect to M staging, PET/MR and the reference
standard showed similar results for M0 staging; however, four
patients showed M1 staging discrepancies between PET/MR
and the reference standard. In one of these patients a skeletal
lesion was not avid on PET/MR and was seen only on the
Fig. 3 Axial CE MR image (a),
PET/MR fusion image (b) and
PET image (c) in a 38-year-old
man (arrows moderately FDG-
avid supraclavicular lymph node)
Fig. 4 Axial PET/MR images in
a 64-year-old woman with lung
cancer in the right lower lobe. The
MR images (a, b) and the
superimposed PET and MR
image (c) show a fat plane
between the mass and the
thoracic vertebra
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follow-up scan. In this patient PET/CT was also normal. One
pulmonary nodule judged positive according to the reference
standard was probably too small to be characterized by the
limited spatial resolution of the PET/MR protocol. This was a
7-mm lesion with a subsolid component. One liver lesion was
misinterpreted on PET/MR staging but was recognized on
follow-up CE CT.
One of the problems of MR is the lower sensitivity for
pulmonary nodule detection compared with the reference
methodology, e.g. PET/CT and diagnostic CT. Several studies
have evaluated the use of MR for nodule detection and dem-
onstrated the limited value of this technique, which is attrib-
utable to the low proton density of lung tissue and the limited
spatial resolution [21, 22]. However, current fast T1-weighted
gradient-echo sequences have improved the depiction of pul-
monary nodules in the range 3 – 5 mm [23, 24]. Even in the
presence of cancer, many pulmonary nodules may be benign,
and indeed this remains a diagnostic dilemma in oncology.
In this study we tried to reproduce and apply a practical
standard MR protocol which consisted of large field of view
T1-weighted and T2-weighted sequences, including DWI,
plus a whole-body gadolinium CE T1-weighted MR scan
combined after PET acquisition in an attempt to reproduce a
‘diagnostic CT protocol’. It has been suggested that the use of
contrast media in MR imaging highlights vessels and hilar
structures, thereby reducing the diagnostic gapwith diagnostic
CT for the assessment of mediastinal and chest wall infiltra-
tion [25]. However, the optimal diagnostic protocol is still a
matter of debate, and particularly the development of new
specific dedicated lung protocols may enhance the diagnostic
value of the MR component.
In addition to the problem discussed above regarding
our reference standard, i.e. not all histology data were
available, our study had some other limitations. We did
not systematically record quantitative FDG uptake, which
would be necessary particularly if we wished to assess
the value of the modality for postoperative staging. In
addition, we performed PET/MR immediately after PET/
CT, and a delay in imaging after injection would have
caused image degradation despite partial compensation
through an increase in acquisition time; furthermore,
accumulation of tracer at more than 90 min after injec-
tion may show different distribution characteristics. We
recognized that this timing could have caused some bias
in the interpretation. However, this approach was done
for ethical considerations since PET/CT was always the
required clinical examination. It is important to underline
that our study aimed to investigate the potential role of
PET/MR in assessing lung cancer resectability and we
demonstrated that PET/MR results are comparable to
published results with PET/CT [26].
Finally, the potential benefits of the individual compo-
nents of the PET/MR were not assessed and such assess-
ment was beyond the purpose of this study that looked at
the value of a “standard” PET/MR protocol, performed
similarly to PET/CT to assess tumour resectability. How-
ever, the encouraging findings of the current study may
form the necessary foundation for further studies, aiming
to prove the added value of PET/MR over conventional
PET/CT, when including various diagnostic MRI se-
quences for specific indications. The results of our study
indicate the relevance of further investigations of simul-
taneous PET/MR imaging particularly with respect to the
multiparametric role of multiple MR sequences.
Fig. 5 ROC curve and AUC for PET/MR in the assessment of resect-
ability in relation to the reference standard
Fig. 6 Axial PET/MR image (a),
PET/CT image (b) and CE CT
image (c) in a 67-year-old man.
An irregular nodule adjacent to
the superior vena cava shows
FDG uptake on both the PET/MR
and PET/CT images although
separated from the mediastinum
by a fat plane
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Conclusion
Our results indicate that simultaneous PET/MR imaging may
be an alternative to PET/CT performed similarly in staging
lung cancer and potentially results in lower radiation expo-
sure. This will need to be balanced by cost and availability
constraints.
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